Remote monitoring of cancer patients with suspected Covid-19 using wearable sensors and regular mobile data networks; results of the RECAP feasibility study (NCT04397705)

Abstract Background: Cancer patients with Covid-19 causing less severe illness have been safely managed in an outpatient setting but they remain at risk of clinical deterioration. In this pilot study we assessed the feasibility of using wearable biosensors to monitor key physiological data in ambulatory, home based, cancer patients with Covid-19 infection. Two key components of feasibility were assessed: patient acceptability of the devices, and the reliability of transmitting the data in real-time to the treating hospital. Methods: Ambulatory cancer patients with Covid-19 consented to wearing sensors monitoring heart rate, respiratory rate, and temperature, along with twice daily pulse oximetry measurements for up to three weeks. All physiologic data were transmitted from home to the treating hospital via a secure cellular data pathway. Data other than oxygen saturations was analysed retrospectively. Questionnaires and semi-structured interviews were completed by patients and thematic qualitative analysis performed. Results: 8 patients (6 female, 2 male) with a median age of 62 years (range 40-73) were recruited. 2 patients completed 21 days on study. 2 patients were admitted to hospital due to decreased oxygen levels. 4 patients discontinued monitoring during the study period. Most participants liked the concept of active monitoring and felt confident about connecting the device and changing the sensors. Others found using the system more challenging. Data transmission was considered good or satisfactory in 5 participants. Conclusions: This is the first study demonstrating the use of wearable sensors to monitor cancer patients at home with real-time transmission of data to the treating hospital. Participants were generally supportive of remote monitoring and most found the technology easy to use but some issues with usability were highlighted. Registration: , The study was registered with Clinical Trials.gov on 21/05/2020, registration number: NCT04397705, https://clinicaltrials.gov/ct2/show/NCT04397705